Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.67 |
| ▸ | FAP | Q12884 | 3/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.67 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.63 |
| ▸ | PREP | P48147 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15855961 | 1.00 | DPP4 (0.69) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL15030434 | 0.87 | DPP4 (0.53) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL17048286 | 0.86 | DPP4 (0.69) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL17048339 | 0.86 | DPP4 (0.69) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL17048338 | 0.86 | DPP4 (0.69) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL7795161 | 0.83 | DPP4 (0.71) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL15024754 | 0.81 | DPP4 (0.69) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL3189715 | 0.81 | DPP4 (1.00) | DPP4DPP8FAPDPP9DPP7 | |
| Vildagliptin SCHEMBL665400 | 0.81 | DPP4 (1.00) | DPP4DPP8FAPDPP9PREP | |
| Vildagliptin SCHEMBL16579 | 0.81 | DPP4 (1.00) | DPP4DPP8FAPDPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788323-B1 | NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN | CHEMELECTIVA SRL (IT) | 2017-01-11 | — | — | EP | disclosed |
| EP-2788323-B1 | NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN | CHEMELECTIVA SRL (IT) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015128718-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | HIKAL LIMITED (IN) | 2015-09-03 | — | — | WO | disclosed |
| US-8877799-B2 | Inorganic salt complexes of vildagliptin | Egis Gyogyszergynar Nyilvanosan Muekoedoe Reszvenytarsasag (HU) | 2014-11-04 | — | — | US | disclosed |
| EP-2788323-A1 | NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN | Chemelectiva Srl. (IT) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013083326-A1 | NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN | CHEMELECTIVA S.R.L. (IT) | 2013-06-13 | — | — | WO | disclosed |
| US-20130005790-A1 | INORGANIC SALT COMPLEXES OF VILDAGLIPTIN | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2013-01-03 | — | — | US | disclosed |
| WO-2011101861-A1 | PROCESS FOR PREPARATION OF DPP-IV INHIBITORS | MSN LABORATORIES LIMITED (IN) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005790-A1 | INORGANIC SALT COMPLEXES OF VILDAGLIPTIN | SLC5A2, SLC5A1, DPP4 | DPP4 3/4885DPP8 8/4885FAP 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.